SCHEMBL7797772

SCHEMBL7797772

CCOC(=O)c1c(Oc2ccc3c(c2)OCO3)cccc1Oc1ccc2c(c1)OCO2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.54
RAB9A P51151 8/20 0.50
NPC1 O15118 7/20 0.50
PRKCI P41743 1/20 0.50
PRKCZ Q05513 1/20 0.50
TP53 P04637 4/20 0.48
MAPK1 P28482 2/20 0.48
PTGS2 P35354 2/20 0.48
TSHR P16473 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 6/20 0.47
ALDH1A1 P00352 6/20 0.47
LMNA P02545 4/20 0.47
HSD17B10 Q99714 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7800988 0.94 MAPT (0.50) MAPTRAB9ANPC1PRKCIPRKCZ
SCHEMBL7799781 0.93 RAB9A (0.50) MAPTRAB9ANPC1PRKCIPRKCZ
SCHEMBL7797779 0.92 MAPT (0.48) MAPTRAB9ANPC1PRKCIPRKCZ
SCHEMBL7790974 0.92 MAPT (0.50) MAPTRAB9ANPC1PRKCIPRKCZ
SCHEMBL7797700 0.90 MAPT (0.47) MAPTRAB9ANPC1PRKCIPRKCZ
SCHEMBL7800900 0.90 MAPT (0.47) MAPTRAB9ANPC1PRKCIPRKCZ
SCHEMBL7800997 0.89 MAPT (0.46) MAPTRAB9ANPC1PRKCIPRKCZ
SCHEMBL7799670 0.89 MAPT (0.48) MAPTRAB9ANPC1PRKCIPRKCZ
SCHEMBL7799198 0.89 MAPT (0.46) MAPTRAB9ANPC1PRKCIPRKCZ
SCHEMBL7791652 0.88 MAPT (0.45) MAPTRAB9ANPC1PRKCIPRKCZ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010014694-A1 Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin ENCYSIVE PHARMACEUTICALS, INC. 2001-08-16 US disclosed
US-6265428-B1 VASODILATION TEXAS BIOTECHNOLOGY CORPORATION 2001-07-24 US disclosed
US-5977117-A Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin TEXAS BIOTECHNOLOGY CORPORATION (US) 1999-11-02 US disclosed
EP-0876364-A2 SUBSTITUTED PHENYL COMPOUNDS AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 1998-11-11 EP disclosed
WO-1997025321-A2 SUBSTITUTED PHENYL COMPOUNDS AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 1997-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010014694-A1 Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin EDNRA, EDNRB, NPR1 MAPT 4496/4885RAB9A 3305/4885NPC1 2650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.